Published in Rev Infect Dis on December 08, 1989
Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis (2006) 2.17
In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother (2002) 1.02
Disseminated zygomycosis due to Rhizopus schipperae after heatstroke. J Clin Microbiol (1999) 1.01
Mucormycosis spondylodiscitis after lumbar disc puncture. Eur Spine J (2005) 0.91
Mucormycosis resulting in gastric perforation in a patient with acute myelogenous leukemia: report of a case. Surg Today (2006) 0.91
Isolated mucormycosis in a post-pyeloplasty kidney in an immuno-competent child. J Indian Assoc Pediatr Surg (2012) 0.90
Hepatic mucormycosis mimicking hilar cholangiocarcinoma: a case report and literature review. World J Gastroenterol (2010) 0.89
Gastric mucormycosis due to Rhizopus oryzae in a renal transplant recipient. J Clin Microbiol (1996) 0.89
Evidence of immunopathological traces in mucormycosis: an autopsy case. Clin Exp Nephrol (2010) 0.77
Mucormycosis and acute kidney injury. J Nephropathol (2012) 0.75
Isolated renal mucormycosis in a healthy immunocompetent patient: atypical presentation and course. Korean J Urol (2013) 0.75
A Rare Cause of Massive Upper Gastrointestinal Hemorrhage in Immunocompromised Host. Gastroenterology Res (2012) 0.75
Renal mucormycosis in immunocompromised patient, treated with Robotic Nephrectomy: Case report and review of articles. Urol Case Rep (2017) 0.75
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol (1993) 5.14
Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol (1980) 4.28
Cryptococcus neoformans mating and virulence are regulated by the G-protein alpha subunit GPA1 and cAMP. Genes Dev (1997) 4.28
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 4.01
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother (1993) 3.79
Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med (1996) 3.76
Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J Clin Invest (1988) 3.69
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother (1986) 3.38
Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol (2001) 3.11
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis (1998) 3.09
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest (1990) 2.91
Infection due to Actinobacillus actinomycetemcomitans: 15 cases and review. Rev Infect Dis (1989) 2.89
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother (1997) 2.76
Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol (1998) 2.30
RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. Mol Microbiol (2000) 2.30
Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis (2006) 2.17
Cryptococcemia. Medicine (Baltimore) (1983) 2.10
Detection and surveillance of colorectal cancer. JAMA (1989) 2.07
Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. J Immunol (1986) 2.06
The G-protein beta subunit GPB1 is required for mating and haploid fruiting in Cryptococcus neoformans. Mol Cell Biol (2000) 2.03
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother (1985) 2.02
Identification of the MATa mating-type locus of Cryptococcus neoformans reveals a serotype A MATa strain thought to have been extinct. Proc Natl Acad Sci U S A (2000) 1.96
Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis (1987) 1.85
Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother (1985) 1.78
Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J (2000) 1.76
The STE12alpha homolog is required for haploid filamentation but largely dispensable for mating and virulence in Cryptococcus neoformans. Genetics (1999) 1.75
Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci U S A (1994) 1.72
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.66
A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol (1999) 1.65
Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol Cell Biol (1999) 1.64
Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs (1997) 1.63
Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. J Infect Dis (1982) 1.58
Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med (1983) 1.56
Dominant selection system for use in Cryptococcus neoformans. J Med Vet Mycol (1997) 1.54
Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis (1999) 1.51
Fungal meningitis. Semin Neurol (2000) 1.50
Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryot Cell (2003) 1.49
Two cyclophilin A homologs with shared and distinct functions important for growth and virulence of Cryptococcus neoformans. EMBO Rep (2001) 1.46
Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 1.42
Signal transduction pathways regulating differentiation and pathogenicity of Cryptococcus neoformans. Fungal Genet Biol (1998) 1.41
Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother (2001) 1.37
Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med (1986) 1.34
Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis (1985) 1.31
Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents. Antimicrob Agents Chemother (1998) 1.29
Influence of agglutinating antibody in experimental cryptococcal meningitis. Br J Exp Pathol (1981) 1.29
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother (1987) 1.27
Diguanidino and "reversed" diamidino 2,5-diarylfurans as antimicrobial agents. J Med Chem (2001) 1.25
Scedosporium species infections and treatments. J Chemother (2003) 1.23
Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immun (1990) 1.23
Cryptococcus neoformans differential gene expression detected in vitro and in vivo with green fluorescent protein. Infect Immun (1999) 1.22
Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med (1984) 1.22
Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia (2011) 1.21
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev (1999) 1.21
The actin gene from Cryptococcus neoformans: structure and phylogenetic analysis. J Med Vet Mycol (1996) 1.21
Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob Agents Chemother (1999) 1.21
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis (2008) 1.20
Effects of cyclosporine in experimental cryptococcal meningitis. Infect Immun (1985) 1.19
Identification and characterization of an SKN7 homologue in Cryptococcus neoformans. Infect Immun (2005) 1.16
Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity. Mol Microbiol (2001) 1.15
Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target. Genetics (1999) 1.15
Macrophage-mediated fungistasis: requirement for a macromolecular component in serum. J Immunol (1986) 1.12
The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J Antimicrob Chemother (1990) 1.12
Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother (2000) 1.12
Fungal scleritis after cataract surgery. Successful outcome using itraconazole. Cornea (1992) 1.11
The Cryptococcus neoformans genome sequencing project. Mycopathologia (1999) 1.10
In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles. Antimicrob Agents Chemother (1998) 1.06
Fatal, disseminated Acremonium strictum infection in a neutropenic host. J Clin Microbiol (1996) 1.03
Comparison of cotrimoxazole, ampicillin, and chloramphenicol in treatment of experimental Haemophilus influenzae type B meningitis. Antimicrob Agents Chemother (1980) 1.02
Biochemical role of the Cryptococcus neoformans ADE2 protein in fungal de novo purine biosynthesis. Arch Biochem Biophys (1998) 1.01
Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS (1996) 1.00
Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) (1996) 1.00
Pneumonia due to Fonsecaea pedrosoi and cerebral abscesses due to Emericella nidulans in a bone marrow transplant recipient. Clin Infect Dis (1995) 0.98
Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy (2000) 0.96
Chemotactic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Sabouraudia (1985) 0.93
Anastomotic infections in lung transplant recipients. Ann Transplant (2000) 0.93
Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis (2006) 0.93
Potential value of cefoperazone in bacterial meningitis: experimental studies. Drugs (1981) 0.92
Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect Immun (1990) 0.91
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation (2001) 0.91
Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant (1998) 0.90
Cryptococcosis and the basidiospore. Lancet (1982) 0.90
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother (1999) 0.90
Agents for treatment of invasive fungal infections. Otolaryngol Clin North Am (2000) 0.90
Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. AIDS Res Hum Retroviruses (1999) 0.89
Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses (1999) 0.89
Retrospective review of amphotericin B use in a tertiary-care medical center. Am J Hosp Pharm (1987) 0.88
Clostridial bloodstream infections. South Med J (1989) 0.87
Pharmacokinetics of cefoperazone, moxalactam, cefotaxime, trimethoprim and sulphamethoxazole in experimental meningitis. J Antimicrob Chemother (1981) 0.86
First report of involvement of Nodulisporium species in human disease. J Clin Microbiol (1994) 0.86
Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother (2008) 0.85
Knockout mice as experimental models of virulence. Med Mycol (2000) 0.85
Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol (2007) 0.85
Efficacy of immune therapy in early experimental Naegleria fowleri meningitis. Infect Immun (1987) 0.85